Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease

描述：由伯氏疏螺旋体引起的莱姆病（LD）可以影响皮肤，心脏，关节或神经系统，导致一系列与其他衰弱疾病重叠的非特异性症状。疾病进展可导致预后不良的疾病发展，如抗生素难治性关节炎或治疗后莱姆病综合征（PTLDS）。早期诊断和治疗是改善疾病结局的关键。目前的检测不能区分疾病的早期和晚期，也不能预测预后。我们建议使用超灵敏微流体技术来开发第一个用于莱姆病血清诊断的快速实验室芯片护理点（POC）定量检测。拟议的POC测试将在一次测试中提供敏感和明确的早期和晚期莱姆病检测和区分。它是一种多功能和信息丰富的一级分析，可以取代目前的双血清学双层标准

DESCRIPTION: Caused by Borrelia burgdorferi, Lyme disease (LD) can affect the skin, heart, joints or nervous system leading to an array of largely non-specific symptoms that overlap with those of other debilitating illnesses. Disease progression can lead to development of conditions with unfavorable prognosis such as antibiotic-refractory arthritis or Post- Treatment Lyme disease Syndrome (PTLDS). Early diagnosis and treatment is key to improving disease outcomes. Current assays do not discriminate between early and late stages of the disease and cannot predict prognosis. We propose to use ultrasensitive microfluidics technology to develop the first quantitative rapid lab-on-a-chip point of care (POC) assay for the serodiagnosis of Lyme disease. The proposed POC test will provide sensitive and definitive detection and differentiation of early- and late- stage Lyme disease in a single test. It is a versatile and informative first-tier assay which can evolve to replace the current bi-serologic two-tier standard of care.